greeksoup/ stock research

OptimizeRx Corp.: Q3 FY2026 earnings call

What management said about Q3 FY2026, from the documents filed with the SEC on 13 November 2026: press release, call transcript. Guidance figures: 1 lowered, 1 kept. The quarter’s numbers.

Key takeaways

  • Revenue fell 17% year over year: Q3 revenue was $21.6 million against $26.1 million a year earlier. Management attributed the decline mainly to reduced spending by a limited number of large customers. Source
  • Net revenue retention fell to 83%: Net revenue retention was 83% on a rolling twelve-month basis, against 121% a year earlier. Management said a few large accounts optimizing spend drove the dip rather than broad churn. Source
  • Displaced top-five client returned: A client that was about 10% of 2025 revenue had no revenue in the first three quarters of 2026. Revenue from it began in Q4, but spending has not yet returned to historical levels. Source
  • Adjusted EBITDA margin near 29%: Adjusted EBITDA margin was about 29% in the quarter, up from about 20% a year earlier. Management attributed the gain to margin optimization and cost management initiatives. Source
  • Contracted 2026 revenue about 20% below: Contracted revenue for 2026 is about 20% below the prior year, so more revenue must be secured and recognized in Q4. Management said this level is largely unchanged from prior quarters. Source
  • 2027 contracted revenue about 20% ahead: Management said contracted revenue for 2027 is about 20% ahead of the prior year during the RFP season. Management said it is too early to give 2027 guidance. Source
  • Debt principal repaid ahead of schedule: Debt was $13.4 million at September 30 and $10.4 million after a further $3 million payment following quarter end. The term loan carries a rate of SOFR plus 2.25%. Source

“Third quarter revenue and adjusted EBITDA both exceeded consensus expectations, reflecting continued margin expansion, disciplined execution, and the resilience of our operating model.”

Stephen L. Silvestro, OptimizeRx CEO

Guidance

AreaPeriodFigureAgainst last quarter
Full-year revenue SourceFiscal year 2026$87-$93 millionLowered from $95-$100 million
Full-year adjusted EBITDA SourceFiscal year 2026$21-$25 millionKept
Full-year gross margin SourceFiscal year 2026low 70% range
Gross margin objective SourceBeyond fiscal 2026, as revenue grows30%-plus

What changed from last quarter

  • Guidance lowered: Full-year 2026 revenue guidance updated to $87-$93 million from $95-$100 million; adjusted EBITDA guidance unchanged. Source
  • Guidance kept: Adjusted EBITDA guidance of $21-$25 million maintained, as stated on the call. Source
  • New: Trade Desk integration announced in September, giving advertisers access through its OpenPath solution. Source
  • New: PulsePoint partnership announced, adding programmatic distribution for the company's network. Source
  • New: Natural Language Audience Builder extended in September to direct-to-consumer audiences. Source
  • New: Sarah Bast joined as Chief Marketing Officer during the third quarter. Source
  • New: Andy D'Silva to become Chief Financial Officer and Heather Favazza Chief Accounting Officer on January 1, 2027. Source

Results and growth drivers

  • Revenue fell 17% year over year: Q3 revenue was $21.6 million against $26.1 million a year earlier. Management attributed the decline mainly to reduced spending by a limited number of large customers. Source
  • GAAP net income rose to $1.2 million: Q3 GAAP net income was $1.2 million, or $0.06 per basic and diluted share, against $0.8 million, or $0.04, a year earlier. Nine-month GAAP net loss was $3 thousand. Source
  • Non-GAAP net income per share rose: Non-GAAP net income was $3.8 million, or $0.20 per diluted share, against $3.1 million, or $0.16, a year earlier. Nine-month non-GAAP net income was $8.8 million. Source
  • Adjusted EBITDA rose while revenue fell: Adjusted EBITDA was $6.3 million in Q3, against $5.1 million in Q3 2025, an increase of about 23% while revenue declined. Source

Customers and segments

  • Net revenue retention fell to 83%: Net revenue retention was 83% on a rolling twelve-month basis, against 121% a year earlier. Management said a few large accounts optimizing spend drove the dip rather than broad churn. Source
  • Top 20 manufacturer revenue per account lower: Average revenue per top 20 pharmaceutical manufacturer was $2.5 million on a rolling twelve-month basis, against $3.1 million. Prior periods were restated under an updated Fierce Pharma list. Source
  • Mid-tier and long-tail accounts growing: Management said mid-tier and long-tail clients are growing well into double digits from last year. Dedicated sales resources cover that segment, and one mid-tier client entered the top 10. Source
  • Displaced top-five client returned: A client that was about 10% of 2025 revenue had no revenue in the first three quarters of 2026. Revenue from it began in Q4, but spending has not yet returned to historical levels. Source

“We believe these developments, along with our continued focus on strengthening our commercial leadership and broadening our product capabilities, position us to capture additional demand and support future growth.”

Stephen Silvestro, Chief Executive Officer

Products and programmatic partners

  • Trade Desk access to 800,000 professionals: Through The Trade Desk OpenPath, advertisers can reach over 800,000 verified healthcare professionals across more than 400 EHR and e-prescribing systems on the OptimizeRx network. Source
  • PulsePoint adds 250,000 incremental NPIs: OptimizeRx will contribute about 250,000 incremental NPIs to PulsePoint's network. Management expects its inventory to reach PulsePoint advertisers during November. Source
  • Three DSPs seen as most of volume: Management estimated DeepIntent, The Trade Desk and PulsePoint represent 60% to 70% of programmatic volume in this space. Revenue from these partners is at an early stage. Source
  • NLAB extended to consumer audiences: NLAB now builds coordinated HCP and consumer audiences in one natural-language workflow, using Micro-Neighborhood Targeting. CopayCue, introduced recently, is also in the product set. Source

Costs, margins and profitability

  • Adjusted EBITDA margin near 29%: Adjusted EBITDA margin was about 29% in the quarter, up from about 20% a year earlier. Management attributed the gain to margin optimization and cost management initiatives. Source
  • Expenses fell $5.1 million year over year: Total expenses fell to $18.9 million, driven by lower cost of revenue and compensation. Severance of $0.7 million tied to a previously announced reduction in force partly offset the decline. Source
  • Cost of revenue fell on product mix: Cost of revenues was $5.4 million, against $8.6 million a year earlier. Management attributed the decrease to a favorable product and channel mix, including lower DTC managed service revenue. Source

“However, this year it's starting to get a little bit baked, which is the reason why we're dialing down our revenue expectations in line with what we're seeing in our backlog.”

Edward Stelmakh, Chief Financial and Strategy Officer

Demand and contracted revenue

  • Contracted 2026 revenue about 20% below: Contracted revenue for 2026 is about 20% below the prior year, so more revenue must be secured and recognized in Q4. Management said this level is largely unchanged from prior quarters. Source
  • 2027 contracted revenue about 20% ahead: Management said contracted revenue for 2027 is about 20% ahead of the prior year during the RFP season. Management said it is too early to give 2027 guidance. Source
  • Just over 90% of guidance contracted: Management said about a little over 90% of the revenue needed for the guidance midpoint is contracted, compared with the mid-90% range in prior years. Source
  • Pent-up demand not yet visible: Management said customers held budgets through the first three quarters and may deploy them later. Visibility into buy-up timing is limited, so management did not build it into guidance. Source
  • Budget pressure and MFN pricing uncertainty: Management cited budget pressures and spending delays from broader market conditions, including MFN pricing uncertainty, as contributors to the year-over-year decline. Source

Capital, cash and debt

  • Debt principal repaid ahead of schedule: Debt was $13.4 million at September 30 and $10.4 million after a further $3 million payment following quarter end. The term loan carries a rate of SOFR plus 2.25%. Source
  • Cash and operating cash flow: Cash and cash equivalents were $22.3 million at September 30, against $23.4 million at December 31, 2025. Operating cash flow for the nine months was $12.9 million. Source
  • Term loan and revolver in place: The company fully drew a $25 million term loan from Fifth Third Bank and has access to a $10 million revolver, following the refinancing of its Blue Torch Capital loan. Source

Strategy and investment

  • Three competitive advantages cited: Management cited an AI-enabled platform, proprietary healthcare data, and an integrated EHR network with more than 450 systems and over 1.1 million verified HCPs as its advantages. Source
  • Four priorities for late 2026: Priorities are top-line execution, wider use of DAAP and NLAB, more network use through programmatic distribution, and continued financial discipline and operating efficiency. Source
  • Platform shift beyond point-of-care marketing: Management described a move from point-of-care marketing toward a platform covering audience intelligence, media planning, programmatic activation, and clinical workflow engagement. Source

People and leadership

  • Ed Stelmakh's final earnings call: This was Ed Stelmakh's last earnings call. He continues as Chief Financial and Strategy Officer through the end of 2026, then as a strategic advisor. Source
  • CMO adds pharma marketing experience: Sarah Bast brings more than two decades of pharmaceutical marketing experience. Management said the appointment supports go-to-market work with manufacturers and agencies. Source
  • Team morale described as high: Management described team morale and business culture as the best in a very long time. Source

Coming up, as management said on 13 November 2026

  • Buy-up activity expected within six weeks: Management said it expects buy-up activity to start within the next six weeks, though timing has limited visibility. Source
  • PulsePoint inventory live in November: Management expects OptimizeRx inventory to be available to PulsePoint advertisers throughout November. Source
  • More equity buyback activity in Q4: Management said more equity buyback activity is expected in Q4. Source
  • Debt paydown to continue early: Management intends to keep paying down loan principal ahead of schedule alongside its share repurchase program. Source
  • 2027 guidance not yet issued: Management said it has not given 2027 guidance yet and did not give a date for it. Source
  • Net revenue retention expected to improve: Management expects net revenue retention to start improving into 2027, depending on how Q4 closes. Source
  • More detail in Form 10-Q: Management said additional information will appear in the upcoming Form 10-Q. Source

Figures management reported

FigureReported
Average revenue per top 20 pharmaceutical manufacturer (rolling twelve months) Source$2.5 million (prior year $3.1 million)
Percent of total revenue from top 20 pharmaceutical manufacturers Source53% (prior year 56%)
Net revenue retention (rolling twelve months) Source83% (prior year 121%)
Revenue per average full-time employee (rolling twelve months) Source$706 thousand (prior year $820 thousand)
Verified healthcare professionals on network Sourceover 1.1 million across more than 450 EHR and e-prescribe systems

Risks management discussed

  • Demand: Management said the revised revenue range raises execution risk, since more revenue must be contracted and recognized in Q4. Source
  • Demand: Management attributed the year-over-year revenue decline mainly to reduced spending by a limited number of large customers. Source
  • Demand: Limited visibility into buy-up spending led management to revise guidance rather than rely on Q4 spending. Source
  • External: Management said pharmaceutical clients are uncertain about how spending will be treated under the change in Congress. Source
  • Demand: Management said revenue from the three programmatic partners is at a very early stage. Source
  • Operational: Management said recognizing revenue requires contracting, delivering and measuring work within a set period. Source

Earlier plans management reported on

  • On track: Management said the finance leadership transition remains on track. Source
  • Met: Management said the cost-reduction initiative was completed during the first half of the year. Source
  • Ahead: Q3 principal payments were $6 million ahead of the payment schedule. Source
  • Not stated: Management said margin optimization initiatives from the last 18 months continue to yield benefits. Source
  • Met: Management said the Blue Torch Capital loan was refinanced with Fifth Third Bank, as previously highlighted. Source
  • Not stated: Management said it previously indicated a shift in capital use toward share repurchases and plans to push harder on the buyback. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.